<DOC>
	<DOCNO>NCT02638714</DOCNO>
	<brief_summary>A single arm , single center trial ass safety efficacy restore function damage optic nerve use autologous purified population bone-marrow derived stem cell ( BM-SCs ) 24 month follow period .</brief_summary>
	<brief_title>Treatment Optic Neuropathies Using Autologous Bone Marrow-Derived Stem Cells</brief_title>
	<detailed_description>Optic nerve atrophy ( ONA ) condition define damage optic nerve harmfully affect central peripheral vision . ONA may occur result optic neuritis , compression tumor aneurysms , toxic nutritional neuropathy , trauma , secondary complication systemic disease diabetes . Symptoms ONA vary diversely , mainly include blurred vision reduction optic sharpness color visualization . ONA irreversible process , current medical strategy focus find underlying cause , try prevent vision loss protect healthy eye . This Single arm , Single Center trial ass safety efficacy purify adult autologous bone marrow derive CD34+ , CD133+ , CD271+ stem cell 24 month follow-up period . The combination three cell type base diverse potentiality differentiate specific functional cell type regenerate damage optic nerve support issue vasculature , availability clinical-grade purification system ( CliniMACS ) Microbeads purify target cell population clinically-approved method . Anticipated outcome study define overall improvement vision , restoration function damage optic nerve , improvement quality life patient .</detailed_description>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Optic Nerve Diseases</mesh_term>
	<criteria>Patient suffer Optic Nerve Atrophy diseases like diabetic retinopathy retinal pigmentation . Age 1855 year old Willingness undergo bone marrow derive autologous cell therapy . Ability comprehend explain protocol Ability willingness regularly visit hospital protocol follow Patients preexist current systemic disease lung , liver , gastrointestinal , cardiac , immunodeficiency , syphilis , clinically relevant polyneuropathies . History life threaten allergic immune mediate reaction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Optic Neuropathies</keyword>
	<keyword>Stem Cell Therapy</keyword>
</DOC>